Att. Docket No. REG 710-A-

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/009,852 Group: 1614

Filing Date: December 6, 2001 Examiner: Unknown

Title: MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES AND METHODS OF MAKING AND USING THEREOF

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231.

Bernadette B. Fahey

January 16, 2003
Date

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56 and 1.97

Assistant Comm. Patent and Trademarks
Washington, D.C. 20231

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and copies of references listed therein. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

[x] (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

or

[ ] (c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

[ ] (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

[ ] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

[ ] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

[ ] (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:

[ ] (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

[ ] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

and

[ ] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).

REQUEST FOR TRANSFER OF REFERENCE COPIES

[ ] Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN _____, filed _____, be transferred to the subject application for consideration by the Examiner

Fees

The fee required for the filing of this Information Disclosure Statement is estimated to be $_____. Applicants hereby authorize such charge to Deposit Account number 18-0650. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-050.

Respectfully submitted

_____

Linda O. Palladino
Reg. No. 45,636
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400

FORM PTO-1449 Att. Docket No.: REG 710-A-US

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN : 10/009,852 Applicant: Papadopoulos, et al.

Date Filed: December 6, 2001

Title: MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES AND METHODS OF MAKING AND USING THEREOF

Examiner: Unknown Group Art Unit: 1614

January 16, 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Publication Number	Publication Date	Name
_____	6,011,003	01/04/00			Charnock-Jones, et al.
	5,712,380	01/27/98			Kendall, et al

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
_____	WO98/13071	04/02/98	PCT			
_____	WO97/44453	11/27/97	PCT			
_____	WO99/03996	01/28/99	PCT			

OTHER DOCUMENTS
(Including Author, Title, Date, Pertinent Pages, etc.)

_____ Terman, B. I., et al, "Identification of a new endothelial cell growth factor receptor tyrosine kinase", Oncogene (1991) 6:1677-1683

_____ Terman, B.I., et al, " Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor", Biochem Biophys Res Comm (1992) 187(3):1579-1586

_____ Tsutsumi, Y., et al, "PEGylation of interleukin-6 effectively increases its thrombopoietic potency", Thrombosis and Haemostasis (1997) 77(1):168-173

_____ Dunca, R. and Spreafico, F., "Polymer Conjugates", Drug Delivery Systems (1994) 27(4):290-306

_____ Hileman, R.E., et al., "Glycosaminoglycan-protein interactions: definitions of consensus sites in glycosaminoglycan binding proteins", BioEssays (1998) 20:156-167

_____ deVries, Carlie, et al., "The *fms*-like tyrosine kinase, a receptor for vascular endothelial growth factor", Science (1992) 225:989-991

_____ Sharifi, J., et al., "Improving monoclonal antibody pharmacokinetics via chemical modification", Quart J Nucl Med (1998) 42:242-249

_____ Jensen-Pippo, K.E., et al., "Enteral bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol)", (1996) Pharm Res 13(1):102-107

_____ Tanaka, K., et al., "Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 Tyrosine kinase)", (1997) Jpn J Cancer Res 88:867-876

_____ Yang, J.C., et al., "The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma", (1995) Cancer 76(4): 687-694

EXAMINER CONSIDERED | DATE

_____ | _____

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By: _____

Linda O. Palladino
Patent Agent for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400